Tests and monitoring

The study links tissue and blood molecular changes to UC severity, suggesting candidate mechanisms (fibrogenesis, neutrophil activation) that could lead to biomarkers or new therapeutic targets. Understanding severity...

Fecal calprotectin measured by a point‑of‑care CGICA assay showed high accuracy for identifying colorectal inflammation and IBD in patients with chronic diarrhea, which could help avoid some unnecessary colonoscopies...

Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.

Patients facing total proctocolectomy may care because the surgical approach can affect the chance of needing to convert to open surgery, how long the operation takes, and the short-term risk of complications like...

A new patient-derived “Colon Chip” reproduces key features of Crohn’s disease and ulcerative colitis in the lab and points to fibroblasts as active drivers of inflammation and early cancer-associated changes — insights...

Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...

A validated human peristaltic intestinal organoid model could make preclinical testing more predictive for drugs affecting gut motility and reduce reliance on animal models.

Pyoderma gangrenosum is an uncommon but important extraintestinal skin complication that can occur with ulcerative colitis and may be mistaken for infection. Recognizing it matters because treatment and wound care differ...

Finding a pathogenic HMBS variant in a child with extensive ulcerative colitis suggests rare genetic conditions (like acute intermittent porphyria) can appear alongside or mimic IBD and might affect symptoms or...

Granulomas are a classic histologic feature of Crohn’s disease, so patients and clinicians may wonder whether their presence predicts worse disease or different treatment needs. This review shows existing studies are...

This study highlights factors—tumor location, age, smoking, and having IBD—that were associated with survival and progression in a Lebanese CRC cohort.

Based on the title and source metadata, this appears to be a patient education related to Tests and monitoring. The original article is from msn.com.

Fecal calprotectin is a noninvasive stool biomarker used to detect intestinal inflammation and to help distinguish IBD from noninflammatory conditions.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and CRP. The original article is from Alimentary Pharmacology & Therapeutics.

The study examines whether recommended management for rectal inflammation in UC is followed in routine care and whether following guidelines affects 12-month remission — important for patients and clinicians aiming for...

Standard measures like BMI and routine labs can miss muscle and fat depletion in IBD patients. Better screening plus access to dietitian assessment could find treatable malnutrition that affects recovery and quality of...

The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...

Self‑management programs delivered by nurses may help people with IBD improve daily functioning, confidence in managing their condition, and quality of life even when inflammation markers don’t change. That matters...

People hospitalized with ulcerative colitis who don’t meet classic severe-disease criteria can still face meaningful colectomy risk. Using a lower CRP cutoff might help clinicians identify more high-risk patients...

Lowering the CRP cutoff could help hospitals identify hospitalized UC patients at higher risk of needing surgery who are currently classified as less severe. That may affect monitoring and treatment decisions during...

PSC can progress to cirrhosis and cholangiocarcinoma; circulating multi-omic signatures that track severity and cancer-associated changes could help explain disease biology and lead to biomarkers for risk stratification...

People with Crohn's disease and their clinicians often ask how different treatments affect cancer risk. This large nationwide study provides real-world estimates of absolute excess cancer cases by treatment group, which...

This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...

Bowel urgency is a common symptom that may predict higher risk of treatment escalation, hospitalization, or surgery in UC even when bleeding and stool frequency look controlled. Better assessment of urgency in clinic...

People with ulcerative colitis undergo surveillance for dysplasia because of an increased risk of colorectal cancer. This case highlights a pathology pattern (pseudocarcinomatous invasion) that can mimic invasive...

A more detailed, reproducible measure of endoscopic inflammation could better reflect total disease burden and reduce variability from human readers. That may matter for monitoring disease activity, judging treatment...

This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...

This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...

Patients and clinicians care about objective, reliable ways to tell if intestinal inflammation is truly healed because histologic healing predicts outcomes.

Changes in gut permeability are thought to relate to intestinal barrier function and symptoms in UC and IBS-D. If Aquamin alters permeability, it could suggest a mechanism for symptom or disease-modifying effects and...

This trial tests mirikizumab (an anti–IL-23p19 biologic) alone and with an oral agent in adults with moderate–severe UC or CD, which could expand treatment options if later-phase trials are successful.

This trial tests whether adding an FXR agonist (LY4395089) to mirikizumab improves endoscopic response in people with moderate–severe Crohn's disease. Results could influence future combination treatment strategies and...

This trial tests a new oral drug for moderate-to-severe ulcerative colitis and could expand treatment options if later shown to be safe and effective. It also targets patients who have had inadequate response or...

This trial tests a common real-world question: switching from IV induction to subcutaneous vedolizumab maintenance in adults with moderate-to-severe UC or CD and measures short-term remission and longer-term treatment...

Surgery is common in Crohn’s disease and different types of resections carry different short-term risks.

Noninvasive monitoring matters for children with UC because endoscopy is burdensome. If ultrasound (and simple measures like bowel wall thickness) can reliably detect moderate-to-severe disease, families may avoid some...

The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...

If you have newly diagnosed Crohn’s disease, this study suggests sacroiliac joint inflammation or structural SIJ changes can already be present and may relate to microscopic (histologic) intestinal activity.

Zinc deficiency is common in UC, and this study suggests that changes in zinc‑dependent enzyme activity in the gut lining are linked with local inflammation. If confirmed, mucosal enzyme activity might help explain...

This is relevant because military aviators with Crohn’s disease have historically been excluded from waivers; policy changes could allow some stable patients to continue flying if objective evidence supports low...

Reliable laboratory methods help ensure upadacitinib tablets contain the correct amount of drug and support quality control of medicines people take for conditions including Crohn’s disease and ulcerative colitis.

Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...

Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...

A new biologic (duvakitug) targeting TL1A showed higher clinical remission at 14 weeks than placebo in a phase 2b trial of adults with moderately to severely active ulcerative colitis, which could expand future treatment...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Journal of Gastroenterology...

If therapies that restore intestinal barrier function can be reliably tested and measured, future treatments might be developed that specifically target barrier healing — a mechanism linked to symptom relief and possibly...

The study shows that more children worldwide are living with early-onset IBD even as mortality has fallen, and it highlights persistent socioeconomic disparities—important for families and clinicians tracking pediatric...

Markers of systemic inflammation (CRP and ESR) were consistently higher in people with obesity across Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis, suggesting body weight may influence...